Search
Amyotrophic Lateral Sclerosis Clinical Trials in Syracuse, NY
A listing of 2 Amyotrophic Lateral Sclerosis clinical trials in Syracuse, NY actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 2 of 2
The city of Syracuse, New York, currently has 2 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
Featured Trial
COPD Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Featured Trial
Child/Teen Migraine Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
HEALEY ALS Platform Trial - Master Protocol
Recruiting
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: SUNY Upstate, Syracuse, New York
Conditions: Amyotrophic Lateral Sclerosis
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/15/2024
Locations: SUNY Upstate Medical University, Syracuse, New York
Conditions: Amyotrophic Lateral Sclerosis
1 - 2 of 2